Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cardinal Health Inc (CAH) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance

Cardinal Health IncTrade
Royal Caribbean Cruises LtdTrade

Price performance (Past 24H)

Key statistics

Cardinal Health Inc vs Royal Caribbean Cruises Ltd — how do they compare? Cardinal Health Inc trades at $237.35 (market cap $55.88B), while Royal Caribbean Cruises Ltd trades at $307.63 (market cap $82.15B). The key difference: Royal Caribbean Cruises Ltd is the larger of the two by market cap, and Royal Caribbean Cruises Ltd pays the higher dividend (1.63%). Which is the better fit depends on your goals.

CAHRCL
Market Cap
$55.88B$82.15B
Sector
HealthConsumer Cyclical
52-Week High
$240.26$365.84
52-Week Low
$146.04$246.71
Enterprise Value
$59.91B$104.79B
Dividend Yield
0.86%1.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cardinal Health Inc

Cardinal Health (CAH) trades at $236.87, down 0.13% on the day, near its 52-week high. The stock shows strong momentum with four consecutive quarterly EPS beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Technical indicators are bullish overall, with moving averages supporting upward trends. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%.

Outlook remains positive driven by robust pharmaceutical demand and optimistic FY2027 guidance. Key risks include high debt levels and thin profit margins. Analysts maintain a bullish consensus with a $266.43 price target, representing 12.5% upside. The stock presents a growth opportunity but requires monitoring of margin pressures and cash flow volatility.

Royal Caribbean Cruises Ltd

Royal Caribbean (RCL) trades at $309.24, up 0.4% with a bullish technical signal. The company shows strong fundamental momentum with Q2 2026 EPS beating expectations at $4.21 vs. $3.98 estimate, and revenue growth accelerating from $8.8B in 2022 to $17.9B in 2025. Net income margin improved to 23.54% while ROE stands at 45.33%. Recent news highlights strong demand and record pricing for 2027 bookings, though geopolitical concerns have slightly tempered European outlook.

RCL presents a compelling growth story with robust earnings momentum and analyst consensus pointing to 11% upside to the $343.09 price target. Key risks include geopolitical impacts on European itineraries, elevated debt levels at $18.47B long-term, and capital-intensive fleet expansion. The stock's premium valuation at P/E 18.97 requires continued execution on growth targets to justify current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cardinal Health Inc

Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Read more on CAH

About Royal Caribbean Cruises Ltd

Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.

Read more on RCL